Division of Metabolic & Endocrine Products director
Executive Summary
Acting Division of Metabolic & Endocrine Products Director Mary Parks will hold the permanent position as of Aug. 6. Parks, former ODE II division deputy director and team leader for lipid-lowering drugs, was promoted to director following the departure of David Orloff Jan. 1 (1The Pink Sheet" Dec. 12, 2005, In Brief)...
You may also be interested in...
Orloff departs FDA
Metabolic & Endocrine Disorders Division Director David Orloff will step down Dec. 30 after 11 years with FDA to become the medical director of contract research organization Medpace, Inc. Orloff announced his resignation Nov. 29. Division Deputy Director Mary Parks will take over as acting director Jan. 1 until a permanent successor is named. Orloff, who oversaw FDA's review of Bristol-Myers Squibb's Pargluva, is one of several top officials to resign since summer, following the departures of Commissioner Lester Crawford and Office of Women's Health Director Susan Wood...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.